Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Well-Differentiated Thyroid Cancers
NCT03109847Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liquid metformin (Aspargo Labs) in myelosuppression, xerostomia, xerophthalmia, dysgeusia, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jan 2017; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
myelosuppressionxerostomiaxerophthalmiadysgeusia
Beyond the preview
Go deeper on NCT03109847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109847.